Monoclonal B-cell lymphocytosis (MBL) is defined as an asymptomatic expansion of clonal B cells with less than 5 × 10 9
/L cells in the peripheral blood and without other manifestations of chronic lymphocytic leukemia (CLL; for example, lymphadenopathy, cytopenias, constitutional symptoms). 1 Approximately 1% of the MBL cohort develops CLL per year. Evidence suggests that nearly all CLL cases are preceded by an MBL state. 2 Our understanding of the genetic basis, clonal architecture and evolution in CLL pathogenesis has undergone significant improvements in the last few years. [3] [4] [5] [6] [7] [8] In contrast to CLL, our knowledge of the genetics in MBL is still very fragmented, with few prior studies focused on the status of selected genetic abnormalities. 1, 9, 10 In addition, previous reports have demonstrated the co-existence of two B-cell subclones in a small subset of MBL cases, 11 and clonal changes in sequential MBL samples measured by IGHV mutational analysis. 12 To better understand the genomic landscape of MBL and clonal evolution overtime, we performed a longitudinal analysis in a cohort of eight MBL cases, analyzed by whole-exome sequencing (WES) at two time points. The criteria for sample selection were that the individual with MBL had a sample collected at diagnosis of MBL and had one additional sample collected more than 30 months apart that had stored cells for bead selection of clonal B cells and normal non-B cells for DNA extraction. Samples for WES were collected on average 65 months apart (median 62.5 months, range 30-91). At the second time point analyzed, four cases were still MBL, whereas the remaining four cases had progressed to detectable lymphadenopathy by physical exam but had not yet required treatment. After the second sample analyzed, cases were followed up for an average of 26 months (median 24 months, range 3-72). Thus, the total median follow-up of the cohort from MBL diagnosis to the final visit was 88 months (average 91, range 75-120). Overall, one case remained as an MBL and the remaining seven cases had now progressed to detectable lymphadenopathy, and three of which required treatment by IWCLL criteria. The follow-up information and time points analyzed are summarized in Figure 1a .
The MBL individuals provided written informed consent for the collection and use of samples for research purposes according to the Declaration of Helsinki. Clinical information of cases analyzed is provided in Supplementary Table S1 . B lymphocytes were enriched from peripheral blood mononuclear cells using the EasySep Human CD19+ Cell Enrichment Kit without CD43 Depletion. T cells were enriched using the EasySep Human CD3 Positive Selection Kit (Stemcell Technologies, Vancouver, BC, Canada) and subsequently were used as germline samples in the sequencing genetic studies. After cell enrichment, all fractions were stained by four-color immunophenotypic analysis to assess sample purity. The following antibody conjugates were used: anti-CD5-fluorescein isothiocyanate, anti-CD16-phycoerythrin, anti-CD19-allophycocyanin and anti-CD3-peridinin chlorophyll protein (Beckton Dickinson, Franklin Lakes, NJ, USA). Flow cytometry analysis was performed using the FACSCalibur (Beckton Dickinson) and data analyzed using Cell Quest software. On the basis of FACS (fluorescence-activated cell sorting) analysis, we observed after enrichment an average of 91% of CD19+ cells (range 76-99%) and 91% of the CD19+ fraction were CD19+/CD5+ cells (range 66-99%). We used the values of the CD19+/CD5+ fraction to calculate the leukemic B-cell fraction and reduce any significant contamination of non-clonal B cells in each biopsy. DNA was extracted from the clonal B cells and non-clonal (that is, T cells) cells using the Gentra Puregene Cell Kit (Qiagen, Hilden, Germany). Extracted DNAs were fingerprinted to confirm the relationship between samples of the same MBL individual and to rule out sample cross-contamination between individuals. In addition, the molecular analysis of IGHV gene family was performed to confirm the existence of one or more B-cell clones (Supplementary Table S2 ). Mononuclear cells were used for this analysis. One microgram of RNA was converted to cDNA using the BioRad iScript cDNA Kit (Hercules, CA, USA). cDNA (2 μl) were amplified in separate PCR reactions for each of the seven IGHV family genes using a consensus sense primer and an IgM antisense primer. The reactions were carried out using the HotStarTaq PCR kit (Qiagen) in a total volume of 50 μl with 20 pmol of each primer. Cycling conditions were 94°C for 15 min followed by 35 cycles of 30 s at 94°C; 1 min at 60°C; 1 min at 72°C; and a final cycle of 72°C for 10 min. PCR products were electrophoresed and visualized with ethidium bromide, purified using the Wizard PCR Prep kit (Promega, Madison, WI, USA) and sequenced using an automated sequencer (Applied Biosystems, Foster City, CA, USA). In those cases where gDNA was used (MBL04 and MBL09), the conditions were the same except that a consensus antisense primer to the IGHJ region was used instead of the IgM antisense primer. Resulting sequences were aligned to germline sequences using ImMunoGeneTics Information (IMGT) System reference sets and IMGT/V-Quest software (http://imgt.cines.fr).
Genomic DNA from each sample was sheared and used for the construction of paired end sequencing library as described in the protocol provided by Illumina. The exome was captured using the Sure Select 50 Mb Exome Enrichment kit (Agilent, Santa Clara, CA, USA) following the manufacturer's instructions. Samples were sequenced using Illumina HiSeq2000. 100 bp paired end reads were aligned to human genome hg19 using Novoalign (Novocraft Technologies, Selangor, Malaysia). Realignment and recalibration was done to take advantage of Best Practice Variant Detection v3 recommendations implemented in the GATK. Somatic singlenucleotide variations (SNVs) were genotyped using SomaticSniper, whereas insertions and deletions were called by GATK Somatic Indel Detector. Each variant in coding regions was analyzed with PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and MutationTaster (http://www.mutationtaster.org/) to predict biological effects. Pair-wise analyses were performed comparing each tumor time point with the germline sample. Variants with read depth less than 10X were excluded from further analysis. To validate the findings obtained from WES and increase the sensitivity of the screening, a panel of 24 genes relevant to CLL (Supplementary  Table S3 ) was sequenced in all MBL samples at both time points. Targeted deep sequencing (TDS) was performed in a Ion Torrent PGM (Life Technologies, Carlsbad, CA, USA) sequencer with an average coverage depth of 630 × (range 506 × -1180 × ). Finally, SNV, insertions and deletions (indels) were visually inspected using Integrative Genomics Viewer (IGV, Broad Institute). Sequencing findings were then integrated with FISH panel data previously performed in these cases (Table 1) .
Overall, an average of 122-fold depth coverage was obtained by WES (range 92 × -178 × ) with an average of 80% of the targeted regions being covered by at least 30 × . We found an average of 6.6 and 7.5 nonsynonymous SNVs and indels at the first and second time points, respectively. The complete list of mutations and the respective allelic fractions is shown in Supplementary  Table S4 . In four cases, we found mutations in driver genes previously identified in CLL, including ATM, DDX3X, EGR2, FBXW7, SAMHD1 and SF3B1. TDS not only validated the WES results, but also identified additional mutations in BIRC3, POT1 and NOTCH1 in regions that were initially missed due to low coverage obtained from WES in those specific regions. We found a fifth case, MBL01, with a damaging mutation affecting PRDM1, a gene frequently inactivated in diffuse large B-cell lymphomas. 13 Of note, FBXW7 was the only gene recurrently mutated in our cohort. All mutations were found in highly evolutionarily conserved regions and considered damaging by PolyPhen and MutationTaster.
In all four cases, we found the mutations in two or more driver genes (Table 1) . Thus, MBL03 has mutations in ATM and POT1; MBL06 has mutations in BIRC3 and FBWX7, MBL08 has mutations in EGR2, FBXW7, NOTCH1 and two independent mutations in SAMHD1, whereas MBL10 has a mutation in SF3B1 and two independent mutations in DDX3X. We analyzed sequential time points to recreate the clonal architecture and evolution. The number of mutations found per case was insufficient to run comprehensive clustering analysis. However, we focused the analysis on the dynamics of mutations found in putative driver genes. In three of the four cases harboring mutations in putative driver genes (MBL03, MBL06 and MBL08), all the mutations were already detected at the first time point analyzed, but mostly found in subclones that either remained stable (MBL03 and MBL06) or become more prevalent overtime (MBL08; Figure 1b ). In the remaining case (MBL10), the first time point analyzed was characterized by the presence of DDX3X (p.I415V) in nearly 50% allelic fraction and a second DDX3X mutation (p.D164G) in 10% of allelic fraction. In the second time point, an increased abundance of p.D164G and reduced abundance of p.I415V were observed. This opposite trend in prevalence suggests the presence of driver mutations in different subclones with alternated dominance between time points. Furthermore, at the second time point, a novel mutation in SF3B1 was found (p.K666Q). This mutation was not identified in the first time point even using deep sequencing. All four cases with putative CLL mutations eventually developed lymphadenopathy and/or required treatment on average 56 months after clinical recognition of MBL compared with an average of 61 months in the remaining cases. In all four samples, the existence of a single B-cell clone was confirmed by molecular analysis of IGHV gene (Supplementary Table S2 ).
Previous studies have identified genetic abnormalities in a subset of MBL, including deletion 13q14 and NOTCH1 mutations. 2, 10 Furthermore, ATM mutations have been found in linkage studies of familial CLL.
14 Our study brings new insights regarding the genomic landscape and clonal architecture of MBL, the precursor to CLL, 1, 15 by identifying mutations in one or more driver genes and confirming the existence of genetic subclones in a subset of MBL cases. Furthermore, our study brings new data providing insight into the temporal succession of genetic events in MBL and CLL pathogenesis. Thus, a recent study has shown the subclonal nature of FBXW7 in all four CLL cases harboring mutations in the gene, suggesting this mutation is a later event in CLL pathogenesis. 5 However, our data demonstrate the existence of recurrent mutations of FBXW7 in the premalignant stages of the disease, and suggest that FBXW7 mutations can be an early genetic event in CLL pathogenesis. Remarkably, we identified tumorigenic mutations on average 60 months before clear disease progression occurred in MBL cases. These findings support the implementation of a targeted sequencing strategy including the subset of putative cancer genes now known to be recurrently mutated in CLL (~20 genes). Using available sequencing technologies, this subset of genes could be easily screened in very high depth coverage, thus providing early identification of oncogenic mutations in small subclones at the MBL phase.
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LPCs are defined by their ability to initiate human leukemia and to proliferate and self-renew in immune-deficient mice. [1] [2] [3] [4] LPCs in persons with acute myeloid leukemia have diverse phenotypes but most are CD34 + CD38 − . 1, 4 Recently, persons with acute myeloid leukemia and high LPCs frequencies in the bone marrow and persons whose bone marrow cells have a gene expression profile typical of LPCs are reported to have worse clinical outcomes following therapy with anti-leukemia drugs. 5, 6 In persons with Ph
− cells were identified as LPCs in the non-obese diabetic/severe combined immunodeficient (NOD/SCID) xenograft assay, 7 but the clinical relevance of this finding, if any, is unknown. CD58 is reported to be overexpressed in leukemia blasts and might be used as a marker of minimal residual disease in persons with B-cell ALL. 8 Higher proportion of CD58 + cells is reported to correlate with better outcomes in B-ALL. 9 In adults with Ph Induction chemotherapy included 1 cycle of a CODP regimen (cyclophosphamide, 750 mg/mE+2, day 1; vincristine 1.4 mg/mE +2, days 1, 8, 15, 22; daunorubicin, 40 mg/mE+2, days 1-3; prednisone, 1 mg/kg/day, days 1-21). Subjects achieving complete remission (CR) received 8 cycles of consolidation therapy including hyper-CVAD B (cycles 1, 3, 5 and 7; methotrexate, 1 g/mE+2, d 1; cytarabine, 1 g/mE+2, q12h, days 2-3) alternating with the hyper-CVAD A (cycles 2, 4, 6 and 8; cyclophosphamide, 300 mg/mE+2, q12h, days 1-3; doxorubicin, 60 mg/mE+2, day 4; vincristine, 1.4 mg/mE+2, days 4, and 11; dexamethasone, 40 mg/day, days 1-4 and 11-14) . Subjects also received imatinib (400 mg/day) during induction and consolidation therapy. After two cycles of consolidation, subjects with a suitable donor including an human leukocyte antigen-matched sibling, an human leukocyte antigen-matched unrelated donor or a human leukocyte antigenhaplotype identical-related donor were advised to receive an allotransplant. [10] [11] [12] Subjects in the chemotherapy cohort received 6 more cycles of consolidation chemotherapy including the Hyper-CVAD B program alternating with the Hyper-CVAD A program followed by maintenance therapy (6-mercaptopurine, 60 mg/mE+2 daily; methotrexate, 20 mg/mE+2 weekly; monthly vincristine (4 mg/day, day 1)/prednisone (1 mg/kg/day, days 1-7) pulse) for 2 years.
Multi-parameter flow cytometry analyses of CD58-FITC (Beckman-Coulter, Brea, CA, USA)/CD10-PE/CD19-APC-Cy7/ CD34-PerCP/ CD45-Vioblue/ CD38-APC (BD Biosciences, San Jose, Accepted article preview online 25 July 2014; advance online publication, 19 August 2014 CA, USA) on gated leukemia blasts was performed using a multicolor MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany). Fluorescence-minus-one controls were used to determine positive events for CD34, CD38 and CD58. There was considerable heterogeneity in expression of CD38 and CD58 (Supplementary Figure 2) 
CD58
− cohort had a lower proportion of CR after the first course of chemotherapy (62% vs 90%; P = 0.03). Median time to achieve CR in the CD34 +
CD38
− CD58 − cohort was significantly longer compared with the other phenotype cohort (median, 56 days vs 32 days; P = 0.04). Significantly, higher levels of BCR/ABL mRNA were detected in subjects in remission in the CD34 + CD38 − CD58 − cohort than persons in remission in the other phenotype cohort especially after the third cycle of therapy. Cumulative incidence of relapse at 3 year in the CD34 + CD38 − CD58 − cohort was significantly higher compared with cumulative incidence of relapse in the other phenotype cohort (60% (54-65%) vs 19% (18-19%) ; P = 0.02). Three-year leukemia-free survival of subjects in the other phenotype cohort was significantly higher than in subjects in the CD34 + CD38 − CD58 − cohort (69% (53-81%) vs 33% (9-60%); P = 0.04). The CD34 + CD38 − CD58 − cohort also had worse 3-year survival than the other phenotype cohort (32% (6-62%) vs 71% (55-82%)), but this difference was not significant (P = 0.07) (Supplementary Figure 3) . In multivariate analyses, the CD34 + CD38 − CD58 − phenotype was an independent risk factor correlated with likelihood of achieving CR (P = 0.03, odds ratio (OR) = 0.4 (0.2-0.9)), relapse (P = 0.03, OR = 3.4 (1.1-10.5)), leukemia-free survival (P = 0.01, OR = 3.1 (1.3-7.4)) and survival (P = 0.03, OR = 2.8 (1.1-6.9)) (Supplementary Table 1 Table 2 ). Bone marrow mononuclear cells were stained with mouse anti-human CD58-FITC Figure 4) . Purity of each fraction was 497%. The anti-CD122 (interleukin-2 receptor β (IL-2Rβ))-conditioned NOD/ SCID xenograft assay was performed by intra-bone marrow injection.
13,14 Doses were 1 × 10E+3, 1 × 10E+4 and 1 × 10E+5/ mouse. We found different engraftment kinetics in the blood of primary and secondary recipients when 1 × 10E+3, 1 × 10E+4 or 
CD58
− cells compared with a recipient transplanted with other phenotype cells. 
− phenotype. The conventional NOD/SCID mouse assay with intravenous injection is widely used to assay human hematopoietic stem cells and LPCs. 1, 4 Recent improvements include depletion of natural killer cells with anti-CD122 antibody and direct intra-medullary injection. 13, 14 Using this improved assay, we found candidate Ph + ALL LPCs in the CD34 + CD38 − CD58 − fraction. Based on these data, we suggest the adverse clinical outcomes associated with the CD34 + CD38
− CD58 − phenotype consistent with biological studies demonstrating that LPCs are quiescent and relatively resistant to chemotherapy. 15 In conclusion, our study suggested that Ph + ALL LPCs are enriched in the CD34 +
CD38
− CD58 − phenotype which translates to adverse clinical outcomes.
The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma Patients with asymptomatic multiple myeloma (AMM) are at risk for development of symptomatic disease requiring therapy, at the rate of about 10% per year, in the first 5 years after diagnosis. 1 However, while some patients with AMM have a relatively low risk approaching that of monoclonal gammopathy of undetermined significance, there is a subset of patients with AMM at very high risk for imminent development of disease complications (that is, within 1-2 years after diagnosis). Such complications may include bone fractures (commonly vertebral compression fractures) or acute renal injury and renal insufficiency, which increase the morbidity and mortality of MM patients. Currently, it is recommended that patients with AMM should be followed closely without therapy; 2 however, a recent clinical trial indicated that for patients at high risk for progression, early intervention may be beneficial. 3 Thus, for these 'high-risk' patients early intervention is now indicated by many experts, 4 in order to avoid catastrophic complications of the disease. Nevertheless, the identification of high-risk patients is challenging and requires the consideration of several different disease characteristics. The Mayo Clinic group recently identified that patients with extensive BM infiltration (⩾60%) or with extremely abnormal free light chains (FLC) ratio (4100) are at very high risk for imminent progression within o2 years from the diagnosis of AMM. 5, 6 Our group has also confirmed that the above risk features identify a subset of patients with AMM at very high risk for progression, within 12-18 months from diagnosis. 7 The Spanish group has proposed more sophisticated criteria, which require high-quality, flow cytometric analysis. 8 In view of the need for widely available methods to identify high-risk patients, imaging studies may offer significant information. Moulopoulos et al. has published since the 90s the prognostic importance of spine magnetic resonance imaging (MRI) for patients with symptomatic 9 and asymptomatic MM. 10 Hillengass et al. 11 published data indicating that patients with more than one focal lesion in whole-body MRI are at high risk for progression to symptomatic disease; however, whole-body MRI is not widely available. Our group also identified abnormal spine MRI (with either a focal or a diffuse pattern) as a factor associated with a high risk of progression to symptomatic MM. 7 Recently the SWOG S0120 study also identified focal lesions in spine MRI as a predictor of disease progression. 12 Thus, it is now increasingly recommended that spine MRI should be considered in the initial workup of patients with AMM with high-risk features and that patients with more than one focal lesion should be considered for early intervention. 4 Herein, we present data from our database of patients with AMM with available spine MRI at diagnosis and with mature follow-up, in order to evaluate the prognostic importance of the presence of focal lesions in spine MRI for the identification of patients with AMM at high risk of progression.
We analyzed the outcomes of 67 patients with AMM and a minimal follow-up of 2.5 years. An experienced radiologist in the field of MM (LM) reviewed all the MRIs using standard criteria. 9, 10, 13 The median age of the patients was 63 years (range 35-88), 63% had immunoglobulin G and 37% immunoglobulin A MM. The median BM infiltration in trephine biopsy was 20% (range 11-90%) and 9% had ⩾ 60% plasma cells. All patients had more than 10% plasma cells probably due to the availability of BM trephine biopsy and immunohistochemistry in all of them. The median serum M-spike was 1.9 g/dl, with 48% having 42 g/dl and 11% having ⩾ 3 g/dl, a figure that is smaller than the one reported in the Mayo Clinic series. 1 Median FLC ratio (involved to uninvolved FLC) was 7.6 (range 1-219) and 11% had FLC ratio ⩾ 100.
After a median follow-up of 4 years (range 2.5-11 years), 21 (31%) patients have progressed to symptomatic MM and the 1-, 2-and 3-year rate of progression to symptomatic MM for the cohort is 13%, 21% and 29%, respectively, with an estimated median time to development of symptomatic MM of 70 months.
At the time of diagnosis 13 (20%) patients had abnormal findings in their MRIs of the spine: 9 (14%) had more than one focal lesion (FL), while 2 had diffuse pattern without focal lesions; 2 patients had only one focal lesion and were excluded from further analysis. Median time to symptomatic MM for patients with more than one focal lesion was 15 months (95% confidence interval 6-26 months), while it exceeded 5 years for patients with no focal lesions (Po0.001), corresponding to a hazard ratio of 7.2 (95% confidence interval 3-18) (Figure 1 ). For patients with more than one FL the 1-year progression to symptomatic MM rate was 44%, the 2-year progression rate was 69% and the 3-year progression to MM rate was 85%. The respective 1-, 2-and 3-year progression rates for those with no FLs was 8%, 13% and 22%, respectively.
We applied previously defined features associated with a high risk of progression (BM infiltration ⩾ 60%, FLC ratio 4100) along with the presence of more than one FL in spine MRI, and 85% of our patients had none of these risk factors and 15% had at least one. Among patients with more than one focal lesion, 6 (67%) had at least one of the other high-risk features, but in three it was the only high-risk feature.
Median time to progression for those with none vs those with at least one high-risk feature was 45 years vs 9 months (Po0.001), 1-year progression rate was 4% and 60%, 2-year progression rate 11% and 71% and 3-year progression rate 21% and 89%, respectively.
Our data support the prognostic importance of the MRI of the spine as a tool for the identification of patients at high risk for progression to symptomatic disease. Our results are in accordance with those reported by Hilengass et al., 11 according to which patients with more than one focal lesion had a median time to progression of 13 months while for those without focal lesion or with one focal lesion the time to progression exceeded 5 years. 11 In the SWOG S0120 study the presence of more than one focal lesion was associated with increased risk of disease progression in the subset of patients with available MRIs of the spine. patients with AMM and normal spinal MRI (vs 17% of patients with abnormal spinal MRI, with either focal lesion or diffuse pattern). However, MRI of the spine is less time consuming and causes less discomfort to the patient, has lower cost than whole-body MRI and is widely available, while it also identifies those patients with AMM at high risk for progression.
In summary, our data support the use of spine MRI as the imaging modality of choice in order to help identify patients with AMM at high risk for progression to symptomatic disease, with an estimated probability of progression of~70% within 2 years from diagnosis. In addition to other widely available prognostic tools (FLC ratio4100, BM infiltration ⩾ 60%) we are now in position to identify patients with AMM who should be offered immediate therapy, just like patients with symptomatic MM. Epigenetic dysregulation represents an emerging paradigm in the pathogenesis of myeloid malignancies, and the pharmacologic targeting of pathways involved in regulating epigenetic modifications is a promising therapeutic strategy. 1 Potential targets include recurrently mutated genes encoding epigenetic modifiers (for example, DNMT3A, IDH1/2, TET2, EZH2), and altered epigenetic modifiers (like mixed lineage leukemia (MLL) fusion genes) that are known to initiate acute myeloid leukemia (AML).
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2 Some leukemias with MLL translocations are dependent on the activity of DOT1L, a histone methyltransferase responsible for trimethylation of histone 3 on lysine 79 (H3K79); small-molecule inhibitors of DOT1L, like EPZ004777, can disrupt leukemic progression. [3] [4] [5] DOT1L inhibitors are in various stages of clinical development for MLL-rearranged leukemias, but it is currently unclear whether these inhibitors may also be active in AML cases that lack MLL rearrangements. We recently developed an in vitro culture system for primary AML cells that captures the genetic complexity of primary AML samples, and that can be used to test the impact of novel pharmacologic agents on AML cells. 6 In vitro testing of primary leukemic samples has been very challenging for DOT1L inhibitors, which requires exposure to cells for more than 1 week. However, with our system, primary human AML cells can be expanded for up to 2 weeks. We used this approach to test the effects of DOT1L inhibition against a set of cryopreserved, genomically characterized de novo AML patient samples, collected through a study approved by the Human Research Protection Office at Washington University School of Medicine after patients provided informed consent.
We first verified the sensitivity of MLL-rearranged primary AML cells to the DOT1L inhibitor EPZ004777. Cryopreserved peripheral blood or bone marrow specimens collected at diagnosis were thawed and expanded for 2-4 days in vitro to allow for cells to recover, and were then incubated with increasing concentrations (0.1-10 μM) of EPZ004777 (or DMSO vehicle control) for a period of 10 days. We initially selected six adult AML samples (including four with MLL translocations and two without) to monitor the influence of EPZ004777 on cell growth. Vehicle-treated cells from each patient expanded at variable rates; however, all samples achieved a minimum of twofold expansion by day 10. Dose-dependent growth inhibition was observed for two of the four MLL rearranged samples (one with MLL-AF6 and one with MLL-AF10) in the presence of EPZ004777. AML cell growth was minimally influenced at the maximum drug concentration in the non-MLL control samples (Figure 1a) . Previous studies performed on cells expressing MLL fusions demonstrated that EPZ004777 reduced cell growth with delayed kinetics; 4 indeed, reduced growth was not evident in the responsive samples for at least 6-7 days. Global levels of H3K79 methylation were reduced following exposure to EPZ004777, and expression of HOXA cluster genes was also decreased, as expected (Supplementary Figure S1) . Each of the two MLL-rearranged samples that failed to exhibit a strong response to EPZ004777 had an MLL-ELL fusion (Figure 1b and Supplementary Table 1 ). The lack of response to EPZ004777 in these cases may relate to the reported absence of DOT1L in the MLL-ELL elongation complex. 7, 8 Figure 1. EPZ004777 alters growth and differentiation of primary AML cells with MLL rearrangements. (a) Impact of EPZ004777 treatment on the growth of primary AML cells with (top panels) and without MLL rearrangements (bottom panels). Absolute cell numbers on the y-axis; note the different scales due to different rates of growth. Cells were expanded using a previously described stromal co-culture technique 6 (also see methods in Supplementary material) in the presence of DMSO or increasing concentrations of EPZ004777 (0.1, 1, 10 μM) over a 10-day period. We also examined the effects of EPZ004777 on myeloid differentiation. Cell surface expression of CD11b and/or CD14 increases as myeloid cells differentiate toward neutrophils or mature monocytes, respectively. Expression of these markers increased in a dose-dependent manner after 10 days of drug treatment in the sensitive samples (Figure 1c, top) . In contrast, the MLL-ELL and non-MLL control samples displayed only modest surface expression changes in the presence of drug (Figure 1c,  bottom) . Morphological examination of the cells corroborated the flow cytometric findings (Figure 1d) . Collectively, these data suggested that this in vitro culture system would be suitable for testing the sensitivity of an expanded panel of primary AML samples to EPZ004777.
We therefore evaluated AML cells with mutations in other epigenetic modifiers (for example, IDH1, IDH2, DNMT3A) or the MLL partial tandem duplication (MLL-PTD). All four cases with MLL-PTD alterations were sensitive to EPZ004777, consistent with a recent report. 9 Additionally, we also observed a potent response to EPZ004777 in an AML sample with a PICALM-MLLT10 fusion, which was predicted from a murine model.
3 Surprisingly, many AML samples without MLL fusions or MLL-PTDs were also highly sensitive to treatment with EPZ004777. While EPZ004777 did not slow the growth of AML samples with isolated DNMT3A mutations (for example, UPN 721214 and 868442), 7/7 samples with canonical mutations in IDH1 (R132H/C) or IDH2 (R140Q) were sensitive. All cases demonstrated a dose-dependent decrease in viable cell numbers (compared to the vehicle control) after 10 days of drug treatment (Figures 2a and b) . Of note, two of the seven samples also had MLL-PTD mutations (Supplementary Table 1 ). For the IDH-mutated samples, treatment with EPZ004777 for 10 days induced greater surface expression of CD11b and/or CD14 than vehicle alone (Figure 2c ). Morphologic differentiation was also apparent (Figure 2d ) in the sensitive samples. In total, 14/23 AML samples were sensitive to EPZ004777. All of the responders had an MLL rearrangement (that was not MLL-ELL), a PICALM-MLLT10 fusion, MLL-PTDs, and/or mutations in IDH1 or IDH2.
In sum, our data suggest that a wider spectrum of AMLs may be responsive to DOT1L inhibitors than originally predicted. While the observed responses of AML samples with MLL-PTDs or the PICALM-MLLT10 fusion were anticipated, the responses of IDH-mutant samples were not. The neomorphic enzymatic activity of mutated IDH1/2 produces 2-hydroxyglutarate (2-HG), an oncometabolite capable of inhibiting enzymes that are involved in a variety of epigenetic processes, including histone and DNA methylation. 10 While IDH-mutated AMLs typically do not show dysregulation of HOXA cluster gene expression (which is common in MLL rearrangements and MLL-PTDs), global levels of H3K79 dimethylation (H3K79me2) have been reported to be modestly increased when either IDH1 or IDH2 are mutated;
10-12 the precise locations of altered sites of H3K79 methylation are not yet known. Regardless, the observations presented here provide an impetus to expand studies of DOT1L inhibitors to AML samples with canonical IDH1 or IDH2 mutations, and to define the mechanisms by which it acts in these cases.
Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study Donor lymphocyte infusions (DLIs) can produce lasting remissions in patients with relapsed chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (SCT), but are less effective in non-CML diseases.
1,2 Chemotherapy-induced lymphodepletion with cyclophosphamide (Cy) and fludarabine (Flu) before DLI has been shown to not only enhance activation of donor lymphocytes but also cause significantly more severe graft-versus-host disease (GVHD) than DLI alone, 3 thus limiting its application. To safely balance the toxic versus beneficial effects of activated donor lymphocytes, we combined prior lymphodepletion with the infusion of donor T cells engineered to carry a suicide gene for treating patients with aggressive hematologic malignancies.
Donor T cells were transduced with gibbon ape leukemia viruspseudotyped retroviral particles harboring a bicistronic Thy1-IRES-TK vector coding for the herpes simplex virus type 1 thymidine kinase (TK) suicide gene and the human CD90 (Thy1) GPI-anchored membrane molecule as a selection marker. Transduced cells were then expanded during 15-19 days and enriched through magnetic selection of CD90 + cells before their infusion, as previously described. 4 This process of transduction/expansion/ selection was associated with a significant increase in the proportion of CD3 + and CD8 + cells, specifically of memory/ activated phenotype (Supplementary Figure 1) . In this phase I/II Accepted article preview online 8 August 2014; advance online publication, 2 September 2014 Histograms represent the mean ± s.e.m. of patient values (n = 9 at day 15, n = 8 at days 30 and 90, n = 7 at day 180, n = 5 at day 270 and n = 3 at day 360). TK transgene was undetectable in patient 3 all along his follow-up. For some patients at some time points, values were not available because of profound lymphopenia or when the follow-up was stopped. Mean values for cell counts were compared between different time points using the two-tailed paired Student's t-test. The degree of significance is indicated as follows: *Po0.05; **Po0.01; ***Po0.001. trial, the safety and efficacy of the combination treatment (Cy-Flu/ DLI-TK) were studied between February and December 2011 in 10 adults with relapsed myeloma (n = 5) or myelodysplasia/acute leukemia (n = 5) in three French centers (Supplementary Table 1) .
Mean age at inclusion was 56 years (range: 44-68). Patients had received SCT from a sibling (n = 8) or a matched unrelated (n = 2) donor since a mean interval of 24 months (range: 6-56) and were free of immunosuppressive therapy at inclusion. following Cy-Flu/DLI-TK for 2 weeks. As shown by flow cytometry analysis and PCR quantification of TK transgene copies, this led to the rapid disappearance of TK + cells in PB and liver. Patient 8 had a grade III cutaneous and digestive GVHD that was treated with intravenous GCV from day 7, leading to rapid clearance of CD90 + cells in PB as attested by flow cytometry analysis. PCR quantification of TK transgene copies was not available at early time points before GCV introduction for this patient owing to very profound lymphopenia. (b) The Cy-Flu/DLI-TK regimen mediates a GVT effect in patient 2 with acute myeloid leukemia harboring a nucleophosmine 1 (NPM1) mutation. The leukemia minimal residual disease follow-up is quantified since SCT as a ratio (%) of mutated NPM1 mRNA copy number on reference beta-glucuronidase mRNA sequence. Table 1 ) previously failed to respond to one standard DLI, whereas others had not received any DLI before inclusion.
After receiving Cy (50 mg/kg at day − 6) and Flu (25 mg/m 2 /day from day − 6 to day − 2) intravenously, patients were infused at day 1 with a mean cell dose of 5. (Figure 1a) . Thereafter, the kinetics of immune reconstitution differed among subpopulations. CD8 + and CD56 + cells had reached pre-depletion values within 2 weeks from lymphodepletion, and had doubled at 8 weeks. It took 8 weeks for B cells to reach pre-depletion values and this was even much slower for CD4 + cells, which reached their baseline level after 1 year (Figure 1a ). T-cell activation and naive/ memory markers were monitored during the 3 months following Cy-Flu/DLI-TK. During that period, we observed a significant increase in the proportion of HLA-DR-expressing CD4 + and CD8 Table 1 ). At day 14 after DLI-TK, patient 9 had a grade I cutaneous GVHD that did not need ganciclovir (GCV) treatment according to protocol guidelines and resolved with local steroids. Patient 8 had a grade III cutaneous and digestive GVHD at day 7 after DLI-TK that was treated with intravenous administration of GCV (5 mg/kg b.i.d.). This led to complete and lasting resolution of symptoms, correlated with clearance of TK + cells in PB (Figure 2a) . Patient 2 had a grade III liver GVHD histologically documented at day 43 after DLI-TK. Treatment with GCV led to the rapid disappearance of TK + cells in PB and liver (Figure 2a ) but without clinical improvement after 2 weeks, so that an additional immunosuppressive therapy with steroids and, secondarily, anti-CD25 monoclonal antibody had to be instituted. Liver tests improved partially with persisting transaminase elevation. To adjust treatment, a second liver biopsy was thus performed to evaluate still active GVHD, but was immediately complicated by an intra-abdominal hemorrhage that was rapidly fatal. This complication was the sole fatal adverse event during follow-up (Supplementary Table 2 ).
In three patients with detectable disease at the time of treatment (myeloma in patients 1 and 5 or acute leukemia in patient 2), we observed a graft-versus-tumor (GVT) effect attributable to the Cy-Flu/DLI-TK (Figures 2b-d) . This effect was durable in patient 5 and patient 2 remained disease-free until her death from liver biopsy complication (Figure 2b ). Two additional patients (no. 3 and 4) who had undetectable disease at inclusion remained disease-free on the long term. Seven out of 10 patients progressed in 10 ± 3 months following Cy-Flu/DLI-TK (Figure 2d ), disease progression being at least transiently sensitive to additional therapy in all but one. With a median follow-up of 22 months after Cy-Flu/DLI-TK, six patients are alive (Figure 2e) , four of them being disease-free.
The present trial represents the first investigation of suicide gene-transduced DLI following a lymphodepletive regimen for malignancy relapse after allogeneic SCT. As in previous phase I/II clinical trials where donor TK + cells have been tested, [6] [7] [8] [9] [10] TK-transduced T cells proved to be safe, with no documented adverse event related to the gene modification. After their infusion, transduced cells expanded in PB in all but one patient.
In this patient, as we never detected any transduced cells even at early time points, it is unlikely that this could have been caused by an immunization against the exogenous TK protein, as described by others. 10 In other patients, the total number of CD90 + cells in the compartment of PB was around 10 7 at day 1, thus representing~2% of the total number of injected cells. This repartition is close to the one of PB lymphocytes, which is known to represent about 2% of the total number of body lymphocytes. At day 30, the peak expansion time, CD90 + cells had increased over 15-fold. Interestingly, (i) the recovering T cells had an activated phenotype and (ii) the recovery and then expansion above pre-lymphodepletion values of the CD8 + and NK cells was much faster than that of CD4 + cells. This should create an effectortuned milieu favorable for a GVT effect.
GCV was used in two patients to control GVHD. In these two patients, GCV led to the rapid elimination of the TK + cells. This was sufficient to control GVHD in one of the patient. In the other, there was only a partial control of disease after 2 weeks of treatment. As GCV treatment led to the disappearance of TK + cells from PB and liver, persisting GVHD was thus related to non-transduced effector cells rather than insensitive TK + cells. TK − cells could have arisen from either non-transduced cells from the DLI, although they represented only 1.4% of infused cells or from T cells surviving to the lymphodepletive treatment. In both cases, lymphodepletion may have favored their activation and proliferation upon alloreactive stimulation. In this patient, a related GVT effect was documented but the long-term evolution of GVHD could not be evaluated because of sudden death following a liver biopsy.
Miller et al., 3 who tested a similar Cy-Flu/DLI approach using the same Cy-Flu doses and schedule, but unmanipulated cells in quite comparable patients, observed a 60% incidence of grade II to IV acute GVHD, higher than the 20% observed in our trial. This discrepancy might be related to the cell dose used as in their study patients received a 20 times higher T-cell dose than in ours (10 8 vs a mean of 5.2x10 6 CD3 + cells/kg). This and the safety profile of the treatment should now prompt to infuse higher doses of transduced cells. Modifications of the transduced cell manufacturing process through the use of additional stimulating cytokines 10, 11 and/or the concomitant depletion of regulatory T cells from the DLI 12 represent promising strategies to improve clinical results. The precise proper effect of lymphodepletion before cell infusion will also need to be validated in controlled trials for future developments. Combination of antitumor agents with DLI 13 or the use of donor T cells encoding a chimeric antigen receptor (CAR) targeting a tumor antigen 14 might be also mandatory to further increase the GVT effect of DLI. In the recent development of CAR T cells, the use of lymphodepletion before cell infusion may help in improving the antitumor effect, 15 whereas the combined use of suicide genes will permit securing the approach in prevision of unexpected adverse events following CAR T-cell infusion. The prognostic value of gene expression profiling (GEP) in multiple myeloma (MM) has been reported by several groups. [1] [2] [3] [4] We have previously published a 70-gene classifier (GEP70) that identifies patients with high risk for short progression-free survival (PFS) and overall survival (OS). 1 The GEP70 model was developed from data on patients enrolled in Total Therapy 2 (TT2). 1 Its discriminatory power has been validated in several published data sets in the transplant, non-transplant and relapse settings (reviewed in Johnson et al. 5 ). We applied the GEP70 model to 56 previously treated patients with available baseline GEP information who were enrolled in Total Therapy 6 (TT6), a Accepted article preview online 31 July 2014; advance online publication, 5 September 2014 tandem transplant trial the details of which are provided in Supplementary Methods. The gene expression profiles have been deposited at the NCBI GEO data repository (http://www. ncbi.nlm.nih.gov/geo/) under GEO accession number GSE57317. Sample procurement and processing for GEP, as well as calculations of the GEP70 risk score, have been reported previously. 1 The estimated 1-year survival was 62% for the high-risk group and 97% for the low-risk group by GEP70 (Supplementary Figure S1A, P o 0.0001) . To investigate whether this striking difference in outcomes was driven by a few genes, all 70 probe sets of the GEP70 risk model were ranked by their P-values, based on univariate Cox regression analysis for OS in TT6 (Supplementary Table S1 ). The five probe sets with the smallest P-values (ENO1, FABP5, TRIP13, TAGLN2 and RFC4) were combined to create a continuous score, using methodology similar to that used to develop the GEP70 model. 1 Because each of the five probe sets had a positive association with short OS in TT6, the GEP5 score was simply the mean of log2 transformed expression levels of the five probe sets. An optimal cutoff for the new risk score (hereafter referred to as GEP5) was then established with the running log-rank test, so that patients with scores higher than the cutoff were deemed to have high-risk MM and others to have low-risk ( Figure 1a) , with an estimated OS at 1 year of 60% and 95%, respectively (1-year PFS 50% and 91%, respectively).
All five genes identified in this study were previously reported to be involved in cell proliferation and have been associated with development and survival in different cancers. ENO1 encodes alpha-enolase. Initiation of translation at an alternative translation start site results in a shorter isoform that produces MYC binding protein 1, which acts as a transcriptional repressor and possibly as a tumor suppressor. 6 Overexpression of FABP5, a member of the family of fatty acid-binding proteins, was associated with poor survival in triple-negative breast cancer and with resistance to all-trans retinoic acid in a preclinical model of pancreatic ductal adenocarcinoma. 7, 8 TRIP13 encodes a hormone-dependent transcription factor that interacts with the ligand-binding domain of thyroid hormone receptors and may play a role in early-stage non-small-cell lung cancer. 9 Association of TAGLN2 overexpression and short survival, metastasis and disease progression has been shown for several cancers. 10, 11 RFC4 encodes the 37-kDa subunit of the replication factor C protein complex, which, together with the proliferating cell nuclear antigen, is required for DNA elongation. 12 Because the number of patients treated on TT6 was relatively small and follow-up short (median follow-up 26.5 months), a larger data set of 275 uniformly treated patients on TT3a with a longer follow-up was then used to investigate the new GEP5 score's applicability to previously untreated myeloma. We validated the new GEP5 cutoff for patients enrolled in TT3b (n = 166). 13 Gene expression data for TT3a and TT3b have previously been published and are deposited in the ArrayExpress archive (http://www.ebi.ac.uk/arrayexpress) under the accession number E-TABM-1138. A new optimal cutoff for the GEP5 model of 10.68 was identified from TT3a using the running log-rank statistics, which identified significant differences in OS and PFS for the groups with high-and low-risk disease. Importantly, these differences are comparable to those obtained by the GEP70 risk model with its established cutoff 1 ( Figure 1b  and Supplementary Figure S1B ). In the validation cohort (TT3b), risk distinction using GEP5 was very similar to GEP70 (Figure 1c and Supplementary Figure S1C ) and both were comparable to results in the TT3a training set. We also applied GEP5 to a publicly available external data set of previously untreated patients (HOVON65/GMMG-HD4, n = 288) 4 as a second validation set, where GEP5 also differentiated between a high-risk and a low-risk population with significantly different survival (Figure 1d) .
In order to address the question whether the five probe sets in the GEP5 were truly the best choice, we randomly selected 10 000 quintuplets from all the probe sets within the 70 gene model to create 10 000 continuous scores using the same methodology as for the GEP5 score. Among the 10 000 random scores tested, only 40 performed better in TT6. Of these 40 only 1 performed better in the TT3 test set and none was superior to GEP5 in the TT3b validation set (Supplementary Figure S2 and Supplementary Table S2) . We also examined randomly selected continuous scores in TT6 with probe sets ranging between 1 and 10. Of a total of 42 485 models considered, only 1236 had a smaller P-value than GEP5 in TT6. Among those 1236 scores, 68 had a smaller P-value when tested in the TT3a test set and none performed better than GEP5 in the TT3b validation set (Supplementary Figure S3 and Supplementary Table S3 ). Although some of these random scores showed a better correlation with survival in single data sets, none were consistently better than the GEP5 score across different data sets. The GEP5 always ranked among the top 2% of all scores in all data sets analyzed (data not shown).
On multivariate stepwise analysis, the GEP5-defined high-risk designation was selected as the most adverse variable linked to inferior PFS, with an estimated hazard ratio of 3.44 (95% CI: 2.02-5.86), whereas the GEP70 model was selected for OS (Supplementary Table S4 ). Table 1 summarizes the univariate survival analysis of the GEP5 and GEP70 models. Cross-tabulation of GEP70 and GEP5 risk (low vs high) for TT3A, and TT3B showed an agreement rate between the two models of 0.89, and 0.87, respectively (Supplementary Table S5 ).
GEP70 and GEP5 currently require the use of microarray technology that interrogates the expression levels of more than 47 000 transcripts and variants simultaneously. To assess whether a more targeted approach, only measuring the expression of a small number of genes, could reliably predict risk in MM, we analyzed 48 RNA samples of previously untreated patients on TT3a and TT3b with available GEP data using the nanoString nCounter, with a code set consisting of all five genes (ENO1, FABP5, TAGLN3, TRIP13 and RFC4) of the GEP5 signature and the housekeeping genes RPL27, RPL30, RPS13, RPS29 and SRP14 (code set sequences are provided in Supplementary Table S6 ). Technical and biological normalization were performed using the nSolver software provided by nanoString. The correlation between microarray and nanoString-based gene expression for all five genes was between r = 0.64 and r = 0.87. Using the normalized nanoString data, we computed a nanoString-based GEP5 score (nsGEP5) applying the same methodology as for the microarray-based GEP5. nsGEP5 and GEP5 correlated very well with r = 0.852 (Supplementary Figure S4A) . The receiver operator curve revealed an area under the curve of 0.897, suggesting that GEP5 high/low risk can be predicted using nsGEP5 (Supplementary Figure S4B) .
In summary, high-risk myeloma remains one of the greatest therapeutic challenges. The striking difference in survival of previously treated patients among GEP70 low-and high-risk groups motivated our search for fewer responsible genes. We indeed identified a set of five genes that are highly predictive of survival in multiple independent data sets. The nsGEP5 based on targeted evaluation of the expression levels of these five genes using the nanoString technology showed a very good correlation with GEP5 (based on microarray data). This new technology could reduce cost and sample requirements and has the great potential of making gene expression-driven risk assessment available to a broader patient population. However, the nsGEP5 will have to be evaluated in an independent homogeneous set of clinical samples before it can be utilized in the routine clinical setting. Recently a large-scale proteomics experiment involving 85 patients with MM identified ENO1, Figure 1 . GEP5 distinguishes a high-and a low-risk group with significantly different OS and PFS in the TT6 discovery set, the TT3A training set, and the TT3B and HOVON65/GMMG-HD4 validation sets. Left panels show overall survival, right panels progression-free survival. (a) TT6 discovery set; (b) TT3A training set; (c) TT3B validation set; (d) HOVON65/GMMG-HD4 validation set (Po 0.0001, all panels).
FABP5 and TAGLN2 among a set of 24 proteins that are associated with short OS.
14 This set of 85 patients included 47 who were enrolled in TT3b. The correlation of expression at both mRNA (via our GEP analyses) and protein levels supports the biological relevance of the genes included in the GEP5 model. Work is in progress to identify agents that can effectively target these prognostic genes.
BB has received research funding from Celgene and Millennium, is a consultant to Celgene and Millennium, and is a co-inventor on patents and patent applications related to use of GEP in cancer medicine that have been licensed to Myeloma Health, LLC. SZU is a consultant to Celgene, Millennium and Onyx. He has received research funding from Onyx and Celgene, and speaking honoraria from Celgene. The remaining authors declare no conflict of interest. There are limited data evaluating efficacy of Pom in high-risk RRMM with prior exposure/refractoriness to Len and how best to Letters to the Editor combine it with other available multiple myeloma (MM) therapies for this patient population. Herein, we are reporting a novel, response-adaptive, phase II clinical trial design that used Pom in high-risk RRMM with sequential addition of specific MM therapies. The study was approved by the UAMS IRB. All subjects were informed of the investigational nature of this study and gave written voluntary consent in accordance with institutional and federal guidelines. Patients with MM and high-risk features that has relapsed or resistant to ⩾ 1 prior MM therapy were eligible for enrollment. High-risk features were defined by having high risk on gene expression profiling (GEP) (GEP 70 2 or GEP80 3 signatures), elevated LDH or having abnormal metaphase cytogenetics at the time of disease relapse or progression. Patients with RRMM over 18 years of age and ECOG performance status 0-2 were eligible. All subjects were required to take aspirin or alternate prophylactic anticoagulation while on study.
Cycle #1 Pom was given at 4 mg orally on days 1-21 q 4 weeks; in the absence of ⩾ PR by the IMWG criteria 4 after two cycles, dexamethasone (Dex, 4-20 mg orally q week) and/or Bor (1.3 mg/m 2 IV days 1,4,8,11) and/or Vorinostat (Vor, 100-200 mg po days 1-21 q 4 weeks) could be added; in the absence of ⩾ PR by IMWG criteria after four cycles, cyclophosphamide (Cy, 300 mg/m 2 q week) could be added. The primary end point was progression free survival (PFS) at 1 year after enrollment; secondary end points included overall survival (OS) and overall response rates (ORR). Univariate and multivariate Cox proportional hazards regression models were used to identify associations between covariates and survival outcomes. OS and PFS were depicted using Kaplan-Meier curves. The overall response rate was defined as the percentage of patients achieving partial response (PR) or better, prior to off-study date. Best response was defined as the best response achieved while enrolled by using IMWG criteria. 4 Toxicity was estimated using the National Cancer Institute Common Toxicity Criteria version 3.0. For Pom pharmacogenomic study, GEP analyses were performed on 18 patients with paired baseline and 48 h post Pom samples. In comparison with other agents, we also investigated expression changes of patients' samples obtained prior to and 48 h after single-agent therapy with thalidomide (Thal), Len, Dex or Bor (see Supplementary file for methodology).
Seventy-one patients with HRMM were enrolled between October 2011 and August 2012 (Table 1) . Baseline patient characteristics included age ⩾ 65 years in 45%, cytogenetic abnormalities in 86%, GEP70 high risk in 14/34 (41%), GEP80 high risk in 28/34 (82%), extramedullary disease in 7/71 (10%) and secondary plasma cell leukemia in 3/71 (4%). In total, 68/71 patients (96%) had a prior autologous stem cell transplant (ASCT), 30/71 (42%) had ⩾ 2 ASCT. Patients had received a median of five prior lines of therapy (range 1-10). All the 71 patients (100%) were Len exposed, 58 (82%) with Len-refractory (Len-R) MM, 64 (90%) with Bor-refractory (Bor-R) MM, and 53 (75%) with dual-refractory (dual-R) MM prior to enrollment.
Thirty-four (48%) patients received ⩾ 6 cycles of treatment, 9 (13%) received ⩾ 12 cycles. Patients who received ⩾ 6 cycles, had addition of Dex (67%), Bor+Dex (18%), Bor+Dex+Cy (12%), Bor+ Dex+Cy+Vor (3%) (Supplementary Figure S1) . As of July 2013, 45 patients (63%) discontinued therapy primarily due to progression or death. Twenty (28%) patients achieved ⩾ PR as best response (1 Len-R, 2 Bor-R, 6 in dual-R), with median DoR for patients ⩾ PR of 3 months (range 0.5-21 months). Regimen(s) used for patients ⩾ PR in each cycle until response were listed in Supplementary  Table S1 and other characteristics of responders were presented in Supplementary Table S2 . Fifty-eight patients (5 Len-R, 8 Bor-R, 43 dual-R) had ⩾ stable disease, giving an overall disease control rate of 82%. The largest changes in serum M protein from baseline were displayed in Supplementary Figure S2 . The OS and PFS for the whole group (n = 71) at 12 months were 63% and 13%, respectively (Figure 1 ). An increased risk for OS was observed among patients with LDH ⩾ 190 U/l (HR = 4.62, Po 0.001), C-reactive protein ⩾ 8 mg/l (HR = 2.13, P = 0.041), hemogloblino 10 g/dl (HR = 3.47, P o 0.001) and albumin o3.5 g/dl (HR = 2.83, P = 0.005) (Supplementary Table S3 ). The most common toxicities were listed in Supplementary Table S4 .
At the false discovery rate of 0.01 by paired significance analysis of microarrays, expression levels of 55 probesets (48 genes) significantly changed in response to Pom treatment (Supplementary Table S5 ). Pathway analysis indicated that these 48 genes were mostly related to cell adhesion, inflammatory and hypersensitivity response, such as ITGB1, ITGB7, LGALS3BP (Lectin), GAS6, LYN, RAC1, PYCARD, CASP1, CORO1B, F11R and DKK1, all with higher expression values observed post Pom. To address the question whether these Pom-induced gene expression alterations were unique to Pom, we also investigated expression changes of purified plasma cells obtained prior to and 48 h after single-agent therapy with Thal, Len, Dex or Bor. We found that all three IMiD class of drugs (Pom, Thal and Len) induce gene expression changes in similar directions which were not observed after Dex or Bor (Supplementary Figure S3) . In addition, we checked the cereblon 5 (CRBN) expression level after 48 h Pom Figure 1 . Kaplan-Meier Estimates of OS and PFS from enrollment.
Letters to the Editor but no significant change was found. However, interferon regulatory factor 4 (IRF4), one of the downstream targets of CRBN previously reported to be critical for myeloma cell survival, 5, 6 was downregulated post Pom treatment (P = 0.001), suggesting a CRBN-dependent anti-myeloma activity for POM. Interestingly, IRF4 expression was also decreased after Dex but not Bor. The zinc finger-containing transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3), can be selectively bound by the CRBN-CRL4 ubiquitin ligase and resulted in ubiquitination and degradation. 7, 8 In myeloma cell lines, it has been reported that Len downregulates IKZF1 and IKZF3 protein levels but not their mRNA levels. 7, 8 In our study, we found that the mRNA level of IKZF1 was significantly upregulated in MM patients after Pom treatment (P = 0.001), which could be a response of MM cells to counter the IKZF1 protein degradation effect of Pom. But no significant change was found for the IKZF3 expression after Pom. Furthermore, we found that the expression-based proliferation index 9 was lower (P = 0.05) after 48 h Pom, which implies the killing effect of Pom towards the malignant plasma cells (more discussion of Pom pharmacogenomic study can be found in Supplementary file).
Pom has shown to be active in RRMM in several singleagent 10, 11 early phase clinical trials and perhaps more pronounced response in combination with steroids. [12] [13] [14] [15] The initial phase I study demonstrated activity with two dosing schedules 10 (MTD = 2 mg QD and 5 mg QOD). The efficacy and safety data from the single-agent phase II study showed an ORR of 63%, including CR in 3 patients (5%), VGPR in 17 patients (28%), and PR in 18 patients (30%). 12 More recently, Pom has been combined with other FDA approved and novel agents for RRMM with response rates varying from 48.5-72% (see Supplementary file for references). There are limited data on the differential efficacy of Pom in RRMM patients based on biologic features of the disease at the time of relapse. In the present phase II trial, a response-adaptive strategy was used to treat RRMM with high-risk features. Pom demonstrates good anti-myeloma activity in a heavily pretreated, high-risk RRMM in combination with other anti-myeloma drugs. We also performed pharmacogenomic analyses utilizing global GEP in a subset of subjects, showing that Pom has a unique CRBNmediated mechanism of action. Given the activity in patients with poor prognostic features, further studies are needed to evaluate Pom in combination with other novel agents in front line setting for high-risk MM, perhaps in a response-adaptive schema.
SZU is a consultant to Celgene, Millennium, Onyx and Sanofi. He has received research funding from ArrayBioPharma, Celgene, Onyx, Janssen, Pharmacyclics, and speaking honoraria from Celgene, Millennium and Onyx. BB has received research funding from Celgene and Novartis. He is a consultant to Celgene and Genzyme and has received speaking honoraria from Celgene and Millennium. BB is a co-inventor on patents and patent applications related to use of GEP in cancer medicine.
AKT-induced reactive oxygen species generate imatinibresistant clones emerging from chronic myeloid leukemia progenitor cells BCR-ABL1 kinase is leukemogenic only when expressed in a HSC with self-renewal capacity, thereby inducing LSC. LSCs are capable of generating large numbers of LPCs: leukemia common myeloid (LCMPs) and leukemia granulocyte/macrophage (LGMPs) progenitors, which cannot self-renew and eventually differentiate to mature elements. In CML blast phase leukemia progenitors (LCMP and LGMP) also display the ability to selfrenew and to sustain leukemogenesis; therefore they are LSC candidates.
CML cells display the signature of genomic instability. 3 Generation of the second and third generation of TKIs (dasatinib, nilotinib and ponatinib) to overcome TKI resistance may result in appearance of novel mutations, including compound mutations (polymutants). 4 We reported that TKI-naive and TKI-treated LSCs and LPCs accumulate high levels of ROS and oxidative DNA damage, producing mutations in BCR-ABL1 kinase causing TKI resistance. 5, 6 There are several possible explanations for persistent elevated levels of ROS and oxidative DNA damage in CML-CP cells surviving TKI treatment. For example, the effect of TKIs on BCR-ABL1 kinase-induced signaling pathways stimulating ROS production may be obscured by growth factors, usually resulting in incomplete inhibition or even stimulation of STAT5, AKT, RAC2 and MAPK. 7, 8 Therefore, instead of developing novel inhibitors to target the elusive BCR-ABL1 kinase, drugs downregulating ROS production should be combined with existing TKIs to prevent mutations and to cause more radical elimination of CML-CP cells.
Phosphatidylinositol 3-kinase (PI3K) kinase-mTOR signaling has been implicated in production of ROS in BCR-ABL1-positive cell lines. 9 Recently we showed that RAC2, a putative downstream effector of PI3K, can alter the electron flow through mitochondrial respiratory chain complex III to elevate ROS in LSCs and LPCs. 8 Here we evaluated the role of AKT serine/threonine kinase, another PI3K downstream effector, in generation of ROS-induced oxidative DNA damage and TKI resistance in LSCs and LPCs.
As described before, AKT and RAC2 were inhibited in BCR-ABL1-positive 32Dcl3 cells by expression of specific dominant-negative mutants AKT(K179M) and RAC(T17N), 8, 10 respectively, and in Lin − CD34 + CML-CP cells by AKT activation inhibitor perifosine 11 and RAC inhibitor NSC23766, respectively (Figure 1a) . Inhibition of AKT did not affect the activity of RAC and inhibition of RAC did not affect AKT activity, clearly indicating that their activation status does not depend on each other.
In the presence of growth factors, AKT(K179M) mutant and perifosine diminished ROS levels in annexin V-negative living BCR-ABL1-positive 32Dcl3 cells and Lin − CD34 + cells, respectively (Figures 1b and c) . Perifosine effectively downregulated ROS in Lin − CD34 + CML-CP cells in the G0/G1, S and G2/M cell cycle phases (Figure 1d) , which was associated with reduction of oxidative DNA lesions, 8-oxoG and DSBs (Figures 1e and f) . Finally, inhibition of AKT either by AKT (K179M) mutant or by perifosine resulted in reduction of accumulation of TKIR clones in BCR-ABL1-positive 32Dcl3 cells (Figures 1g and h) .
To determine if AKT is responsible for overproduction of ROS in imatinib-treated LSCs and LPCs, Lin −
CD34
+ CML-CP cells were incubated with imatinib in the presence of growth factors, and ABL1 and AKT activation and ROS levels were measured. Despite inhibition of ABL1 kinase activity, AKT activation was mostly preserved in imatinib-treated Lin − CD34 + cells (Figure 2a ), in concordance with other report. 7 As expected from previous studies with PI3K inhibitors LY294002 or wortmannin and BCR-ABL1 kinase inhibitor imatinib, 13 targeting AKT, a downstream effector of PI3K, with perifosine enhanced the inhibitory effect of imatinib on clonogenic growth of Lin 
+ CML-CP cells treated with 10 μM AKT inhibitor perifosine, 25 μM NSC23766 or diluent (C) 8, 11 were tested for activation of AKT and RAC. Western analyses detect AKT phosphorylated on serine 473 (AKT-pS473) and Rac bound to GTP, as described before; 8, 12 total levels of AKT and RAC were also determined as loading controls. 
+ CML-CP cells were left untreated (black bars) or incubated with 10 μM perifosine (grey bars) in the presence of growth factors. 8 (c) ROS were measured with DCFDA in annexin V-negative cells as described before. 5, 8 (d) ROS were detected by DCFDA in G1, S and G2/M phases, determined by Vybrant DyeCycle Orange live cell staining (Invitrogen/Molecular Probes) as described before. 8 ROS measurements are shown on the left side, and percentages of cells in cell cycle phases are indicated at the bottom. (e) 8-oxoG and (f) γ-H2AX detected by specific immunofluorescence as described before. 8 (g,h) BCR-ABL1-positive 32Dcl3 cells transfected with AKT(K179M) mutant or empty plasmid (g) and untreated (Control) or treated with 1 μM perifosine (h) were cultured for 10 weeks. The frequency of TKI-resistant (TKIR) clones was determined as described before. 8 *Po0.05. 
+ CD38 − LSCs, intrinsic differences between leukemic progenitor and stem cells may contribute to the selective AKT effect in LPCs. 15 Moreover, it remains to be determined if AKT and RAC employ overlapping or different downstream signaling pathways.
and IPSS. A Cox regression model including prognostic factors and platelet response as covariates was used to predict overall survival in romiplostim-treated patients. Poisson regression models, including baseline platelet count, IPSS status and platelet response as covariates, were used to predict bleeding events and platelet transfusions in romiplostim-treated patients. As this was an analysis based on response, a landmark sensitivity analysis was performed using platelet counts from the first 26 weeks to determine platelet response, excluding patients who discontinued the trial within 26 weeks, and analyzing outcomes that occurred after 26 weeks; survival curves by response status were plotted per landmark at week 26. CSBEs were too infrequent for the landmark sensitivity analysis to be meaningful. Overall survival was recorded up to the last observation in long-term follow-up, and bleeding events and platelet transfusions were measured in the extended treatment period only.
The six platelet response measures (Table 1a) were used to evaluate changes in platelet counts in the 58-week placebocontrolled trial in post hoc analyses. Patients (placebo, N = 83; romiplostim, N = 167) were mostly male (59.2%) and Caucasian (94.0%). Median (Q1, Q3) age was 70.0 (61.0, 77.0) years and median (Q1, Q3) baseline platelet count was 19.3 (12.5, 30.3) × 10 9 /l. Median (Q1, Q3) MDS duration was 0.44 (0.13, 1.74) years. Most patients were MDS WHO classification refractory cytopenia with multilineage dysplasia (67.6%).
Romiplostim treatment was significantly associated with platelet response by all criteria studied (Table 1b) . For example, romiplostim-treated subjects were 15.6 times more likely to have hematologic improvement-platelet (HI-P) than placebo-treated subjects. All platelet response criteria also reflected whether patients required platelet transfusions, with nonresponders having more platelet transfusions than responders.
The association between platelet response criteria and clinical outcomes such as bleeding (all and CSBE) were evaluated, as in Table 1b . All response criteria showed significant association between response status and overall bleeding events, with nonresponders being more likely than responders to have bleeding events. Only HI-P, complete response as presented by the Italian MDS group, 10 and durable response were significantly associated with less CSBE. These same measures, and International Working Group (IWG) 2000 criteria, were significantly associated with improved overall survival. Survival curves for HI-P, the platelet response measure most significantly associated with survival, are shown in Figure 1 for romiplostim-treated patients. AML rates for romiplostim-treated patients with HI-P as compared with those without HI-P were similar, 8.5% vs 8.3%, with an odds ratio (95% confidence interval) of 1.02 (0.31, 3.38).
Landmark sensitivity analyses were performed for all measures described above to determine whether this being an analysis based on response and discontinuation of patients affected trial results. For the overall survival end point, after excluding patients who discontinued in the first 26 weeks, the sample size decreased from 167 to 143. Among the 24 subjects who were excluded, 12 died. Smaller sample size and fewer events contributed to slightly larger P-values, although results were generally consistent with the original analyses. Differences included that complete response 10 and IWG 2000 major response 11 were marginally significantly associated with overall survival (P = 0.077 and 0.053, respectively). All platelet response measures remained significantly associated with all bleeding and platelet transfusions (data not shown).
Data from this large placebo-controlled romiplostim trial indicate that platelet response criteria, developed empirically from clinical experience and trials using disease-modifying agents, are heterogeneous, result in a wide range of response rates for the same patient population and are predictive of clinical outcomes in thrombocytopenic MDS patients treated with a thrombopoietin mimetic. This is in keeping with the finding that thrombocytopenia per se has been associated with worse prognosis in MDS, including an increased risk of disease progression. [1] [2] [3] For the first time, we show that platelet response to a thrombopoietin mimetic is positively associated with overall survival. Possibly, romiplostim has a beneficial effect through reducing potentially life-threatening thrombocytopenia or other as-yet-unrecognized broader effects. Thrombopoietin has previously been shown to stimulate other hematopoietic lineages. 12 It is unclear whether the improved outcomes are associated with response to romiplostim or that, inherently, patients that respond have better outcomes. While no difference in survival was seen with romiplostim vs placebo, 7 better selection of patients could lead to improved survival outcomes with romiplostim.
A positive association between treatment and survival is also seen for the disease-modifying therapy azacitidine in higher-risk MDS. 13 For studies examining survival and treatment with erythropoiesis-stimulating agents (ESAs) in MDS, results have been mixed. A retrospective multivariate analysis of patients treated with ESAs with or without granulocyte colony-stimulating factors (G-CSFs) reported that survival, but not disease progression, was improved in the ESA-responsive cohort compared with an untreated IPSS/IMRAW (International MDS Risk Analysis/Workshop) cohort.
14 Another multivariate analysis, comparing patients treated with ESAs plus G-CSFs with a control cohort of untreated MDS patients, found better survival with ESA treatment, particularly for those requiring fewer than two red blood cell units transfused per month. 15 However, a small randomized phase 3 Eastern Cooperative Oncology Group (ECOG) study of patients receiving supportive care alone or supportive care plus ESAs with or without G-CSFs found no difference in survival, and that survival was increased for those who responded to ESA treatment. 16 Whether ESA treatment improves survival in MDS may become clearer as ongoing studies report results.
In summary, these data indicate that platelet response criteria, specifically those that incorporate durable response, such as IWG 2006, correlate with overall survival and have the potential to be used as interim markers for clinically significant outcomes. However, a limitation of this data set is that the study drug treatment was ended early owing to concerns regarding transient increases in peripheral blast cell counts with romiplostim that put patients at risk for the diagnosis of and treatment for AML. Therefore, the data set was incomplete, and it is possible that different results regarding the association of platelet response measures and clinical outcomes would have been obtained with a Figure 1 . Survival curves. Shown are the survival probability for those who had achieved an IWG 2006 HI-P response (red dashed line) and those who did not (solid blue line), all in romiplostimtreated patients. Number of patients at risk is shown on the graph immediately above the x axis. P = 0.0070 by log-rank test.
fuller data set. Evaluation is needed of these associations in either past MDS clinical trials of interventions to raise platelets or future ones to confirm that these findings occur in the broader context.
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to the fact that a large majority of patients were very rapidly admitted, and that ATRA was rapidly started, as soon as APL was suspected by bone marrow morphology: 51% of our patients received ATRA on the day of admission, 68% received ATRA on the day bone marrow aspirate was done and only 25% received ATRA 41 day after admission. Altman et al. 10 reported that the percentage of ED secondary to bleeding increased significantly when the onset of ATRA was delayed beyond the day APL was suspected. In our study, we found no significant difference between patients who experienced ED and those who achieved CR when analyzing intervals from hospital admission to ATRA onset, but the number of patients with delay in treatment onset was quite small. Also of note was the fact that, in our report, all patients were diagnosed and treated after 2006, whereas the five previous reports analyzing EDs in APL included patients often diagnosed in the 1990s, when the importance of rapid onset of ATRA treatment was possibly less appreciated. Moreover, in a recent Canadian study, ED rate improved over time, suggesting that the importance of rapid treatment was less appreciated in the 1990s.
